Professor Ian M. Adcock, PhD, FRSB, FBPhS, FERS - Navigating the Relationship Between Type 2 Inflammation and Uncontrolled, Moderate to Severe Asthma: Identifying Eligible Patients for Targeted Biologic Therapy - a podcast by PVI, PeerView Institute for Medical Education
from 2022-05-04T02:14:14.081685
Go online to PeerView.com/KGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses the relationship between type 2 inflammation and moderate to severe asthma and the use of targeted biologic therapies as treatment. Upon completion of this activity, participants should be better able to: Explain the relationship between type 2 inflammation and moderate-to-severe asthma, biomarkers such as blood eosinophils, and other comorbid conditions, Identify patients with uncontrolled moderate-to-severe asthma who are eligible for targeted biologic therapies based on clinical characteristics of type 2 inflammation, Develop treatment plans for patients with uncontrolled moderate-to-severe asthma according to updated evidence-based guidelines and the latest clinical data on efficacy and safety regarding targeted biologic therapy.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education